Mehmet Ali ÖZCAN, Servet AKAR, İnci ALACACIOĞLU, Özden PİŞKİN

Plasma Thrombin Activitable Fibrinolysis Inhibitor Levels in Behçet´s Disease

Aim: The precise pathogenetic mechanisms causing thrombotic complications in Behçet´s disease (BD) are still not known. To explain the pathogenesis with coagulation induction or a defective fibrinolysis superimposed on endothelial dysfunction, various hemostatic parameters were studied. Thrombin activatable fibrinolysis inhibitor (TAFI), downregulating plasmin generation and fibrinolysis, is a novel risk factor for thrombotic disorders. We studied plasma TAFI levels in BD in comparison with healthy controls. Materials and Methods: Twenty-three patients with BD (mean age: 38.3 ± 10.83, M/F: 5/18) diagnosed according to the criteria of the International Study Group and 20 healthy volunteers (mean age: 38.05 ± 6.29, M/F: 9/11) were enrolled in this study. Patients with liver or renal disease, diabetes mellitus, coronary artery disease, hemophilia, antiphospholipid antibody positivity or using oral contraceptive drugs were excluded from the study. Plasma TAFI levels were determined by using an ELISA test. Results: The mean TAFI antigen levels were 8.40 ± 1.81µg/ml in BD patients and 7.30 ± 0.64 µg/ml in healthy volunteers. A statistically significant difference was found between TAFI antigen levels of these two groups (P = 0.01). Conclusions: TAFI antigen levels were found to be increased in BD, regardless of thrombotic events. To clarify the exact role of TAFI in thrombotic complications of the disease, future studies including more patients with and without thrombosis are needed.

Anahtar Kelimeler:

Behçet’s disease, TAFI, fibrinolysis, coagulation

Plasma Thrombin Activitable Fibrinolysis Inhibitor Levels in Behçet´s Disease

Keywords:

Behçet’s disease, TAFI, fibrinolysis, coagulation,

PDF

___

Oner AF, Gurgey A, Gurler A, Mesci L. Factor V Leiden mutation in patients with Behcet’s disease. J Rheumatol 1998; 25: 496–498.
Toydemir PB, Elhan AH, Tukun A, Toydemir R, Gurler A, Tuzuner A et al. Effects of factor V gene G1691A, methylenetetrahydro- folate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombosis in Behcet’s disease. J Rheumatol 2000; 27: 2849–2854.
Mishima H, Masuda K, Shimada S, Toki N, Tsushima H, Gocho M. Plasminogen activator activity levels in patients with Behcet’s syn- drome. Arch Ophthalmol 1985; 103: 935–936.
Mosnier LO, von dem Borne P, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y. Insulin resistance is associated with increased circulating level of thrombin activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665.
Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-368.
Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activatable fib- rinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001; 1: 59 –74.
Bouma BN, Meijers J. New insights into factors affecting clot sta- bility: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Semin Hematol 2004; 41(Suppl 1): 13–19.
Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). 1566–1574.
Alacacioglu I, Ozcan MA, Alacacioglu A, Polat M, Yuksel F, Demirkan F et al. Plasma levels of thrombin activatable fibrinoly- sis inhibitor in normal and preeclamptic pregnant women. Thromb Res 2004; 114: 155–159.
Nalcaci M, Pekcelen Y. Antithrombin II, protein C and protein S levels in patients with Behcet’s disease. J Int Med Res. 1998; 26(4): 206–208.
Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, López-Soto A et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomod- ulin. Am J Med. 2002; 112(1): 37–43.
Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB et al. Thrombin activatable fibrinolysis inhibitor in Behcet’s disease. Thromb Res 2005; 115: 287–292.